Allarity Acquisition Corp., sponsored by Allarity Therapeutics’ wholly owned subsidiary, is pursuing a proposed IPO with a $100 million base size and $115 million maximum if the over-allotment option is fully exercised. The transaction is expected to leave Allarity’s working-capital outlook unchanged through summer 2028.

Key Highlights

  • Allarity Therapeutics said the proposed transaction does not change its expectation of sufficient working Capital through summer 2028.
  • Allarity Acquisition Corp. has applied to list units on Nasdaq under ALLNU, with shares and warrants expected to trade separately under ALLN and ALLNW.
  • Allarity Acquisition Corp. is pursuing a proposed initial public offering with a $100 million base size.

Allarity Acquisition Corp. sponsored by Allarity Therapeutics, Inc. (NASDAQ: ALLR), is pursuing a proposed initial public offering with a base size of $100 million. The offering could reach $115 million if underwriters exercise the over-allotment option in full.

Jesper Hoiland, a current Allarity board member and former executive vice president and president of Novo Nordisk, is expected to chair Allarity Acquisition Corp.’s board. The units have been proposed for Nasdaq listing under ALLNU.

Working Capital Outlook Remains Unchanged

Allarity Therapeutics said the proposed offering does not alter its expectation of having sufficient Working Capital to fund operations into summer 2028. The registration statement remains preliminary and subject to completion and has not become effective. Securities may not be sold, and offers to buy may not be accepted, before the registration statement becomes effective.